Skip to main content

Table 1 Analysis of All Drug-Related and Post-Therapy Adverse Events

From: Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin

Adverse Event Placebo + Metformin
(N = 17)
RE 500 mg + Metformin
(N = 16)
RE 750 mg + Metformin
(N = 17)
All Adverse Event (AE) N(%)
 Any AE 3 (18%) 6 (38%) 4 (24%)
 Diarrhoea 1 (6%) 3a (19%) 1 (6%)
 Nausea 1a (6%) 1 (6%) 1 (6%)
 Thirst 1 (6%) 0 1a (6%)
 Vomiting 0 1a (6%) 1 (6%)
 Dizziness 0 1 (6%) 1 (6%)
 Supraventricular tachycardia 0 1a (6%) 0
 Urinary tract infection 1b (6%)   0
 Dyslipidemia 0 1b (6%) 0
  1. AE Adverse event, RE Remogliflozinetabonate a determined to be drug related adverse event, one of 3 events of diarrhoea with RE 500 mg + Met determined to be drug related, b post therapy adverse events occurred after last dose